These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 35296557)

  • 81. Re: Immune System and Intestinal Microbiota Determine Efficacy of Androgen Deprivation Therapy Against Prostate Cancer.
    Feng D; Wang J; Wu R; Li D
    Eur Urol; 2024 May; 85(5):498-499. PubMed ID: 38369423
    [No Abstract]   [Full Text] [Related]  

  • 82. A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy.
    Lv W; Shang H; Pei X; Chen Y; Xie H; He D; Wang X; Li L
    Int Urol Nephrol; 2017 Jan; 49(1):61-67. PubMed ID: 27837416
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Pharmacological inhibition of the Notch pathway enhances the efficacy of androgen deprivation therapy for prostate cancer.
    Cui J; Wang Y; Dong B; Qin L; Wang C; Zhou P; Wang X; Xu H; Xue W; Fang YX; Gao WQ
    Int J Cancer; 2018 Aug; 143(3):645-656. PubMed ID: 29488214
    [TBL] [Abstract][Full Text] [Related]  

  • 84. SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.
    Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Itsumi M; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    Eur J Cancer; 2015 Sep; 51(14):1962-9. PubMed ID: 26169017
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Long-Term Outcomes of Whole Gland Salvage Cryotherapy for Locally Recurrent Prostate Cancer following Radiation Therapy: A Combined Analysis of Two Centers.
    Chin JL; Lavi A; Metcalfe MJ; Siddiqui K; Dewar M; Petros FG; Li R; Nogueras González GM; Wang X; Nair SM; Ward JF; Pisters L
    J Urol; 2021 Sep; 206(3):646-654. PubMed ID: 33908799
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer.
    Rafiei S; Gui B; Wu J; Liu XS; Kibel AS; Jia L
    Mol Cancer Res; 2019 Jan; 17(1):263-276. PubMed ID: 30224544
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Is the duration of castration resistance predictive for sequential treatment responses in the metastatic castration-resistant prostate cancer setting?
    Dülgar Ö; Özyükseler DT; Başak M; Ay S; Tural D; Yıldırım ME; Gümüş M
    J Oncol Pharm Pract; 2021 Sep; 27(6):1388-1394. PubMed ID: 32847482
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Recent Development and Future Prospects of Molecular Targeted Therapy in Prostate Cancer.
    Zhang J; Sun J; Bakht S; Hassan W
    Curr Mol Pharmacol; 2022; 15(1):159-169. PubMed ID: 34102978
    [TBL] [Abstract][Full Text] [Related]  

  • 89. The impact of long-term androgen deprivation therapy on cognitive function and socioeconomic decision making in prostate cancer patients.
    Holtfrerich SKC; Knipper S; Purwins J; Castens J; Beyer B; Schlomm T; Diekhof EK
    Psychooncology; 2020 Aug; 29(8):1338-1346. PubMed ID: 32539186
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer.
    Kim M; Lee J; Jeong CW; Ku JH; Kim HH; Kwak C
    Urol Oncol; 2015 May; 33(5):203.e1-9. PubMed ID: 25726498
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN.
    Saad F; Small EJ; Feng FY; Graff JN; Olmos D; Hadaschik BA; Oudard S; Londhe A; Bhaumik A; Lopez-Gitlitz A; Thomas S; Mundle SD; Chowdhury S; Smith MR
    Eur Urol; 2022 Feb; 81(2):184-192. PubMed ID: 34916086
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study.
    Fuccio C; Schiavina R; Castellucci P; Rubello D; Martorana G; Celli M; Malizia C; Profitos MB; Marzola MC; Pettinato V; Fanti S
    Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):1985-9. PubMed ID: 21732105
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Framework of Intrinsic Immune Landscape of Dormant Prostate Cancer.
    Wong NKY; Dong X; Lin YY; Xue H; Wu R; Lin D; Collins C; Wang Y
    Cells; 2022 May; 11(9):. PubMed ID: 35563856
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy.
    Thomas AM; Fidelle M; Routy B; Kroemer G; Wargo JA; Segata N; Zitvogel L
    Nat Rev Clin Oncol; 2023 Sep; 20(9):583-603. PubMed ID: 37365438
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Gut dysbiosis promotes prostate cancer progression and docetaxel resistance via activating NF-κB-IL6-STAT3 axis.
    Zhong W; Wu K; Long Z; Zhou X; Zhong C; Wang S; Lai H; Guo Y; Lv D; Lu J; Mao X
    Microbiome; 2022 Jun; 10(1):94. PubMed ID: 35710492
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy.
    Terrisse S; Zitvogel L; Kroemer G
    Microb Cell; 2022 Dec; 9(12):202-206. PubMed ID: 36483309
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Prostate cancer microenvironment: multidimensional regulation of immune cells, vascular system, stromal cells, and microbiota.
    Chen L; Xu YX; Wang YS; Ren YY; Dong XM; Wu P; Xie T; Zhang Q; Zhou JL
    Mol Cancer; 2024 Oct; 23(1):229. PubMed ID: 39395984
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Gut microbiome: a novel preventive and therapeutic target for prostatic disease.
    Cao H; Zhang D; Wang P; Wang Y; Shi C; Wu H; Du H; Zhang W; Gou Z; Zhou H; Wang S
    Front Cell Infect Microbiol; 2024; 14():1431088. PubMed ID: 39135640
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Icaritin-curcumol activates CD8
    Xu W; Li Y; Liu L; Xie J; Hu Z; Kuang S; Fu X; Li B; Sun T; Zhu C; He Q; Sheng W
    J Exp Clin Cancer Res; 2024 May; 43(1):149. PubMed ID: 38778379
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Prostate Tissue Microbiome in Patients with Prostate Cancer: A Systematic Review.
    Ward Grados DF; Ergun O; Miller CD; Gaburak P; Frimpong NA; Shittu O; Warlick CA
    Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.